AAN 2018: Additional biomarker and vaccine responses announced for ocrelizumab in multiple sclerosis

Earlier this week at the American Academy of Neurology’s (AAN) 70^th Annual Meeting (21–27 April, CA, USA), neurologists from Penn Medicine (PA, USA) have presented their findings from two studies that investigate the impact of ocrelizumab in multiple sclerosis (MS) patients.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please Login or Register to view this area.

biomarkers multiple sclerosis ocrelizumab vaccine